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My research was focused on the role of homocysteine (Hcy) in 
atherosclerotic manifestations of native coronary arteries and venous 
grafts. 
The coronary artery disease (CAD) and its severe manifestations and 
complications are a major cause of premature mortality in developed 
societies. 
Degenerative diseases of native coronary arteries 
Coronary sclerosis is a set of progressive reactions arising from chronic 
injuries of the endicardial surface. The damaged endothelial area is 
filtrated with oxidized lipoproteins and forms a lipid-rich necrotic core 
and a fibrous cap. The lesion is slowly calcifying, however the marginal 
areas remain permanently infiltred by inflammatory cells. 
Degenerative diseases of vein grafts 
Except from left anterior descending coronary artery, saphenous venous 
grafts are used widely for coronary artery bypass grafting (CABG) due 
to their number and size variety and easy accessibility or their easier 
preparation. But their long term patency is seriously limited. After ren 
years only 50-60% of the vein grafts remain functional. The vein graft 
atheromas are different from the native vessels’ similar lesions: diffuse, 
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circular, contains less calcification, fibrin hat is thinner or absent, they 
are prone for rupture and emboli formation. According to experimental 
models, vein grafts have different gene regulation and gene expression 
mechanisms and inflammatory responses caused by inflammation. 
Physiology of homocysteine 
Homocysteine (Hcy) is a sulfur-containing amino acids, an 
intermediate product of the protein metabolism. The Hcy connects three 
different pathways of the amino acid metabolism: the folate and the 
methionine cycle, which provides C1-particules for DNA-, RNA-, and 
protein-, as well as glutathione synthesis. The plasma total Hcy level 
differs by age, sex and race. In healthy adults is between 7-14 µmol/L. 
Hyperhomocysteinemia 
According to our resent knowledge only > 15µmol/L plasma Hcy has 
pathological role and it is listed into different cathegories of mild (15-
30 µmol/L), moderate (30-100 µmol/L) and severe (> 100 µmol/L) 
hyperhomocysteinemia (hHcy). The homocysteine metabolism is 
influenced by several exogenous and endogenous factors. For the 
highest Hcy elevation is caused by the inherited deficiency of 
cystathionine-beta-synthase (CBS) enzyme that is responsible for 
homocysteine-metionin transformation. Other common causes of Hcy 
level elevation are: nutrition deficiency, lack of vitamine B6-, vitamin 
B12-, and folic acid, increased intake of methionine, alcoholism, 
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smoking, coffee consumption, permanently inactive lifestyle. 
Homocysteine level is also affected by certain diseases, eg. diabetes, 
cancer (breast-, ovary-, pancreas carcinoma, acute lymphoblastic 
leukemia), renal insufficiency, psoriasis, SLE, rheumatoid arthritis, 
hypothyroidism, certain neurological diseases (eg. dementia), 
medications: MTX, cyclosporine, trimethoprim, contraceptives, folic 
acid, B6-, B12- antagonists, anticonvulsants, thiazide diuretics, nitrogen 
oxides, fibrates, metformin. 
The „excess” of homocysteine forms disulfide bonds, affects 
thrombocite aggregation and adhesion, increases TXA2-, but reduces 
prostacyclin levels and induces vascular inflammation. Changes 
balance of endogenous fibrinolysis by increasing resistance of fibrine 
clots against of fibrinolysis, increase risk of vascular thrombosis. The 
hHcy facilitates formation of of oxidized LDL, and cholesterol esters 
and their deponation into endothelial lesions. Throughout incorporating 
into proteins Hcy generates an autoimmune response. 
Hyperhomocysteinemia and cardiovascular disease, vitamin 
prevention trials 
In the 1960s based on observations of McCully on homocysteine was 
clarified its relationship with atherosclerosis and thromboembolism. In 
1975 he has published with Wilson the "protein theory" of 
atherosclerosis (between homocysteine and atherosclerosis) and about 
its vitamin prevention. Clinical studies performed since the middle of 
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1990s have verified the independent risk factor role of hHcy in 
cardiovascular and athero-thrombotic disorders, but the combined 
incidence of cardiovascular disease that was achieved by combined 
vitamin therapy has set contradictory results. 
Most of the randomized, controlled studies have shown that reduction 
of plasma Hcy levels by administration of vitamin B6-, or B12- or folic 
acid does not improve outcomes of cardiovascular disease. The key of 
understanding the homocysteine paradox is clarifying its complex 
biochemical role. 
2. OBJECTIVES 
The following objectives were set up: 
1-2. What are the features of medium to long-term manifestations of 
native coronary atherosclerosis and venous graft degeneration 
associated with homocysteine? 
3-4. Is there a relationship between homocysteine and other risk 
factors? 
5. Is there a possible a role of homocysteine in estimation related to 
coronary and vein graft disease progression in order to improve the 
effectivity of secondary prevention? 
3. METHODS 
Design of study for native coronaries 
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A case-control study: comparing CAD patients with "negative" CAD 
controls based on coronary angiographies. We examined risk factors 
profile differecy beween patient and control groups by collecting data 
retrospetively from clinical database.  
Our aim was to investigate the CAD specific risk factors between 
patient groups by collecting data from clinical database. The control 
group was formed by patients who were admitted with suspected CAD, 
but coronary lesions were not confirmed. 
Design of study for venous grafts 
Correlation evaluation between risk factors and graft status among 
patients who underwent CABG surgery, and received at least one 
saphenous vein graft. The coronary tests has been performed at least 
one year after heart surgery, and was based on clinical indications. 
The research was carried out between 2001-2013, in a single center, at 
the University of Debrecen Dept. Of Cardiology in harmony with the 
Declaration of Helsinki and authority regulations. The research has 
been notified to the Institutional Ethics Commission. The involved 
patients received prior oral and written information about the possibility 
of processing data for research. They all gave their written consent, 
which was archived together with their clinical documentation. 
Data was collected from electronic database (MedSolution) of the 
Institute of Cardiology Clinical Center University of Debrecen. Data of 
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personal identification (name, date of birth, social security number), 
was masked throughout the statistical analysis. The physical 
examination and collection of data for all patients was performed by 
me. 
Selection of patients with native coronaries 
A 1010 patients were included among those admitted to DE KK 
Institute of Cardiology during 2001-2002 with suspected CAD, 
performed a selective coronary angiogram. 
Selection of patients with vein grafts 
The study included 237 (two hundred thirty-seven) patients who were 
admitted to DE KK Institute of Cardiology during 2001-2002, followed 
by CABG with at least one saphenous vein graft. 
Recorded data 
For the patients included the following data were recorded: family 
history of atherosclerosis/complications, previous myocardial 
infarction, hyperlipidemia, smoking history and habits, high blood 
pressure, diabetes, carotid stenosis, peripheral arterial vascular disease, 
women's hormonal status. The following demographic information was 
recorded: age (years), sex, body weight (kg), height (meters), body 
mass index, vital signs, and left ventricular ejection fraction, cardiac 
function. 
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Coronary and vein graft status clarification 
Selective angiography examinations and their assessment were carried 
by experienced cardiologists. The standard test methodology was done 
throughout right femoral artery approach by Judkins technic. The 
standard views consisted of at least 3 shots of the left coronary 
artery/graft branches and of two standard view shooting 12.5 frames/ 
sec speed from the right coronary branches by Philips Integris type of 
x-ray machine (Inturist ViewerLite Suite v1.0, Philips, The 
Netherlands). Assessment of coronary artery lumen diameter narrowing 
consisted of determinating localisation and degree of stenoses (%). The 
number of grafts, their localization and graft interventions have been 
documented. 
Coronary angiographies performed within a year after CABG have 
been excluded from evaluation – to separate cases due to technical error 
or premature graft thrombosis. 
The diagnosis of SVG disease was based on independent judgement of 
repeat coronary angiographies by 2 expert cardiologists; SVGs were 
classified according to their “lumen status” (diameter stenosis; [%]) at 
repeat coronary angiography as “intact” with a <20% lumen diameter 
reduction, “narrowed” with a lumen diameter stenosis between 20-
99%, and “occluded” (closed lumen). Patients having >1 SVG with 
different graft status at follow up were ranked according to the more 
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severe graft’s status for classifying the patients to one of the three 
groups. 
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4. RESULTS 
Results of native coronary arteries 
The average plasma Hcy was elevated in all groups (> 15 µmol/L), 
however, women without significant coronary stenosis had lower levels 
of Hcy compared with men. Women but not men with CAD+MI+ had 
significantly elevated Hcy levels comparing to controls. Hcy levels of 
females were lower than of males in the absence of significant coronary 
stenosis. This difference disappeared in the presence of CAD. Adjusted 
Lp(a) levels were significantly elevated only in the CAD+MI+ group in 
both genders. Moderate hyperhomocysteinemia (Hcy>15 mol/L) 
independently of other risk factors was associated with CAD OR: 2.27. 
Isolated Hcy elevation resulted in a tendency of increased risk of CAD 
with or without MI. In females elevated Hcy didn’t increase the risk of 
CAD, while an OR of 2.03. Simultaneous elevation of Hcy and Lp(a) 
resulted in an OR of  2.05 for CAD in the total group and OR of 3.59 
in females. 
Results of vein grafts 
Mean patient age was 57.5±10.4 years. The main reason of post-CABG 
repeat coronary angiography was stable angina and more than 2/3 of 
patients showed vascular signs of SVG disease (stenosis/occlusion). 
Demographics, medical history, indication of repeat coronary 
angiography, clinical parameters or risk factors did not differ 
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significantly between patient groups. A significant positive correlation 
was found between the following parameters: CRP and SVG (luminal 
narrowing (%/month)), Hcy and SVG, CRP and Hcy, while a 
significant but negative correlation was seen between triglycerides and 
HDL-cholesterol. By stepwise forward multivariate linear regression 
analysis, only Hcy levels were associated independently with percent 
SVG lumen diameter stenosis: a 1µmol/L increase in Hcy levels was 
associated with a 0.066% increase in lumen diameter stenosis/month (r 
= 0.752; p<0.01), based on the corresponding patient coronary 
angiograms. Theoretically this means that an increase of 10 µmol/L in 
Hcy levels during 5 years can anticipate an 32,1% stenosis on the SVG.  
5. DISCUSSION 
Results of native coronary arteries 
Both Hcy and Lp(a) elevations were independently associated with 
CAD and/or MI only in women. The association of elevated Lp(a) with 
CAD and MI resulted in an OR of 1.64 for CAD and 1.89 for MI in 
women, respectively. The development of CAD and the onset of acute 
thrombosis in the coronary vessels leading to acute myocardial 
ischemia are very complex and multi-factorial processes, where the key 
players can interact with each other and one can modify another’s 
effect.  
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Simultaneous elevation of Hcy and Lp(a) resulted in an OR of 3,5 for 
CAD in women. In atherothrombotic diseases the clotting/fibrinolytic 
system related factors seem to play a role more prominent in females 
than in males.  
Results of vein grafts 
The patency rate of SVGs observed throughout the 5.6-year 
follow up was 74.4%. Results of the univariate analysis suggested 
a correlation between CRP and the time proportional extent of 
SVG disease as well as between CRP and Hcy in SVG disease. 
During further evaluation by multivariate regression analysis, 
only plasma Hcy levels have remained to be a significant 
independent predictor of the time proportional extent of SVG 
disease. Our conclusion was that plasma Hcy is an independent 
prognostic factor of mid-term post-CABG graft degeneration. In 
our patients elevated Hcy level was a significant positive 
predictor of SVG outcome (graft diameter reduction (%)/month): 
1μmol/L increase of plasma Hcy level was associated with 
0,053%/month graft diameter reduction - theoretically this meant 
that +10 µmol/L increase of Hcy level may result 32.1% of lumen 
diameter reduction within 5 years. 
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The role of homocysteine in estimation of risk of CAD/SVG 
disease progression and its prevention 
The risk of cardiovascular disease is the result of different risk factors 
to be relevant in certain patient groups. Veeranna and colleagues have 
evaluated the role of homocysteine in two clinical trials: MESA (Multi-
Ethnic Study of Atherosclerosis) and NHANES III (Third National 
Health and Nutrition Examination Survey) among more than 12 
thousand patients. By adding homocysteine to Framingham Risk Score 
survey it has increased risk of cardiovascular events According to their 
data, at more than 20% of individuals had to be modified the earlier risk 
category. Ruijter and colleagues in 2008 in the British Medical Journal 
published their research, where more than 300 subjects were collected 
and analyzed the data of classic risk factors and biomarkers of 
cardiovascular mortality. Very elderly patients without a history of 
cardiovascular disease homocysteine itself could identify high risk 
patients, while the Framingham risk score did not. The American Heart 
Association previously suggested to screen homocysteine: 
1. As part of homocystinuria diagnosis 
2. in case of vitamin B12 or folate deficiency  
3. more precise calculation of cardiovascular risk 
Assessing risk for patients and their relatives (<45 years) thrombotic 
events. Specially if classic risk factors are not present. 
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The European Society of Cardiology guideline for the prevention of 
cardiovascular disease lists homocysteine as a second-line risk factor. 
6. NEW RESULTS 
1. Elevated plasma homocysteine is linked with the presence of 
coronary artery disease and myocardial infarction independently 
2. An interaction can be assumed between elevated plasma 
homocysteine and lipoprotein (a)  
3. The simultaneous elevation of plasma homocysteine with 
lipoprotein (a) indicates increased two-fold risk in general, and 3,5-
fold risk among women for coronary artery disease 
4. In the event of increased plasma homocysteine and lipoprotein (a) 
younger (<55év) women have a higher risk of myocardial infarction 
5. increase of homocysteine in long term (> 5 years) forecasts a 
remarkable degree of vein graft diameter reduction 
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